» Authors » Andrii Bazylevich

Andrii Bazylevich

Explore the profile of Andrii Bazylevich including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 83
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Bazylevich A, Miller A, Tkachenko I, Merlani M, Patsenker L, Gellerman G, et al.
Pharmaceutics . 2025 Jan; 16(12. PMID: 39771591
Here, we report on the synthesis and biological evaluation of a novel peptide-drug conjugate, P6-SN38, which consists of the EGFR-specific short cyclic peptide, P6, and the Topo I inhibitor SN38,...
2.
Panja A, Sharma V, Mitra P, Bazylevich A, Drori C, Kayet A, et al.
Bioorg Med Chem . 2024 Jun; 109:117794. PMID: 38875875
Dolastatin 10 (Dol-10), a natural marine-source pentapeptide, is a powerful antimitotic agent regarded as one of the most potent anticancer compounds found to date. Dol-10 however, lacks chemical conjugation capabilities,...
3.
Kobzev D, Prasad C, Walunj D, Gotman H, Semenova O, Bazylevich A, et al.
Eur J Med Chem . 2023 Mar; 252:115298. PMID: 36966651
Here, we report on the design, synthesis, and biological evaluation of a new theranostic antibody drug conjugate (ADC), Cy5-Ab-SS-SN38, that consists of the HER2-specific antibody trastuzumab (Ab) connected to the...
4.
Semenova O, Kobzev D, Hovor I, Atrash M, Nakonechny F, Kulyk O, et al.
Pharmaceutics . 2023 Jan; 15(1). PMID: 36678875
Antibiotic resistance of pathogenic bacteria dictates the development of novel treatment modalities such as antimicrobial photodynamic therapy (APDT) utilizing organic dyes termed photosensitizers that exhibit a high cytotoxicity upon light...
5.
Furman O, Zaporozhets A, Tobi D, Bazylevich A, Firer M, Patsenker L, et al.
Pharmaceutics . 2022 Jul; 14(7). PMID: 35890400
The epidermal growth factor-epidermal growth factor receptor (EGF-EGFR) pathway has become the main focus of selective chemotherapeutic intervention. As a result, two classes of EGFR inhibitors have been clinically approved,...
6.
Rozovsky A, Ebaston T, Zaporozhets A, Bazylevich A, Tuchinsky H, Patsenker L, et al.
RSC Adv . 2022 May; 9(56):32656-32664. PMID: 35529716
Conjugation of an anticancer drug with a cancer-specific carrier and a fluorescent dye to form a theranostic system enables real time monitoring of targeted drug delivery (TDD). However, the fluorescence...
7.
Thankarajan E, Tuchinsky H, Aviel-Ronen S, Bazylevich A, Gellerman G, Patsenker L
J Control Release . 2022 Feb; 343:506-517. PMID: 35150812
Photodynamic therapy (PDT) utilizing an organic dye (photosensitizer) capable of killing cancer cells in the body upon light irradiation is one of the promising non-invasive treatment modalities for many cancers....
8.
Thankarajan E, Walunj D, Bazylevich A, Prasad C, Hesin A, Patsenker L, et al.
Photodiagnosis Photodyn Ther . 2022 Jan; 37:102722. PMID: 35032703
A facile synthesis, biological evaluation and photodynamic properties of novel activatable anticancer molecular hybrids (chimeras) Ch and I-Ch are described. The chimeras consist of DNA methylating methyl triazene moiety and...
9.
Gutman H, Bazylevich A, Prasad C, Dorfman O, Hesin A, Marks V, et al.
ACS Med Chem Lett . 2021 Oct; 12(10):1596-1604. PMID: 34676042
We developed a highly potent anticancer agent, dolastatinol, which is a methylene hydroxyl derivative of dolastatin 10. Dolastatinol is a synthetic analog of dolastatin 10, synthesized by a solid-phase peptide...
10.
Mishra A, Parvari G, Santra S, Bazylevich A, Dorfman O, Rahamim J, et al.
Angew Chem Int Ed Engl . 2021 Feb; 60(22):12406-12412. PMID: 33621382
Amino acid and peptide couplings are widely used in fields related to pharma and materials. Still, current peptide synthesis continues to rely on the use of expensive, water sensitive, and...